Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OTS964 hydrochloride (OTS964) 是一种口服有效的,高亲和力和选择性的 TOPK 抑制剂,IC50为 28 nM。它也是一种细胞周期蛋白依赖激酶 CDK11抑制剂,结合 CDK11B 的 Kd 值为 40 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 547 | 现货 | ||
2 mg | ¥ 783 | 现货 | ||
5 mg | ¥ 1,270 | 现货 | ||
10 mg | ¥ 1,990 | 现货 | ||
25 mg | ¥ 3,890 | 现货 | ||
50 mg | ¥ 5,570 | 现货 | ||
100 mg | ¥ 7,790 | 现货 | ||
500 mg | ¥ 15,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,250 | 现货 |
产品描述 | OTS964 hydrochloride (OTS964) is a potent and selective TOPK inhibitor with potential anticancer activity. |
靶点活性 | TOPK:28 nM |
体外活性 | OTS964 inhibits the growth of TOPK-positive cells with low IC50 values [A549 (31 nM), LU-99 (7.6 nM), DU4475 (53 nM), MDAMB- 231 (73 nM), T47D (72 nM), Daudi (25 nM), UM-UC-3 (32 nM), HCT-116 (33 nM),MKN1 (38 nM), MKN45 (39 nM), HepG2 (19 nM), MIAPaca-2 (30 nM), and 22Rv1 (50 nM)], whereas its growth inhibitory effect against TOPK-negative HT29 cancer cells is significantly weaker, with IC50 of 290 nM. Although OTS964 reveals some suppressive effect on Src family kinases, the response to OTS964 in these cancer cells is not correlated with the expression of Src family kinases c-Src, Fyn, and Lyn, supporting the TOPK-dependent growth inhibitory effects of OTS964. Time lapse imaging in T47D cells shows that treatment with OTS964 induces cytokinesis defects followed by apoptosis |
体内活性 | Although administration of the free compound induces hematopoietic adverse reactions (leukocytopenia associated with thrombocytosis), the drug delivered in a liposomal formulation effectively causes complete regression of transplanted tumors without showing any adverse reactions in mice. Inhibition of TOPK activity with the liposomal OTS964 suppresses tumor growth through induction of cytokinesis defects and subsequent apoptosis. Although oral administration of OTS964 causes some hematopoietic toxicity, this is a transient effect. The spontaneous recovery from leukocytopenia is occured and the anticancer effectiveness of the oral drug is similar to that of the liposomal formulation, oral administration of the drug may prove to be more practical |
细胞实验 | Cell lines:?A549 cells, LU-99 cells, DU4475 cells, MDA-MB-231 cells, T47D cells, Daudi cells, UM-UC-3 cells, HCT-116 cells, MKN1 cells, MKN45 cells, HepG2 cells, MIAPaca-2 cells, 22Rv1 cells and HT29 cells Concentrations: --Incubation Time: 72 h Method: Cells (100 μl) are plated in 96-well plates at a certain density. The cells are allowed to adhere overnight before exposure to compounds for 72 hours at 37°C. Plates are read with a spectrophotometer at a wavelength of 450 nm. All assays are carried out in triplicate. After measuring IC50 values, we calculates the z scores to produce P values. After log transformation (base 10) of IC50 values (nM), the mean and SD are calculated for the log values of the IC50 for the 13 TOPK-positive cell lines.Method: Cells (100 μl) are plated in 96-well plates at a certain density. The cells are allowed to adhere overnight before exposure to compounds for 72 hours at 37°C. Plates are read with a spectrophotometer at a wavelength of 450 nm. All assays are carried out in triplicate. After measuring IC50 values, we calculates the z scores to produce P values. After log transformation (base 10) of IC50 values (nM), the mean and SD are calculated for the log values of the IC50 for the 13 TOPK-positive cell lines. |
动物实验 | Animal Models: BALB/cSLC-nu/nu miceFormulation: 5% glucoseDosages: 40 mg/kgAdministration: i.v. |
别名 | OTS964 |
分子量 | 428.97 |
分子式 | C23H24N2O2S·HCl |
CAS No. | 1338545-07-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 1 mg/mL (2.33 mM)
DMSO: 79 mg/mL (184.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.3312 mL | 11.6558 mL | 23.3117 mL | 58.2791 mL |
DMSO | 5 mM | 0.4662 mL | 2.3312 mL | 4.6623 mL | 11.6558 mL |
10 mM | 0.2331 mL | 1.1656 mL | 2.3312 mL | 5.8279 mL | |
20 mM | 0.1166 mL | 0.5828 mL | 1.1656 mL | 2.914 mL | |
50 mM | 0.0466 mL | 0.2331 mL | 0.4662 mL | 1.1656 mL | |
100 mM | 0.0233 mL | 0.1166 mL | 0.2331 mL | 0.5828 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
OTS964 hydrochloride 1338545-07-5 Apoptosis Cell Cycle/Checkpoint MAPK CDK TOPK inhibit Inhibitor Cyclin dependent kinase OTS964 OTS-964 Hydrochloride OTS 964 OTS-964 hydrochloride OTS964 Hydrochloride OTS-964 OTS 964 Hydrochloride inhibitor